In summary, our findings confirm blood borne ST6GAL1 levels are increased in men diagnosed with prostate cancer, and further show levels of ST6GAL1 are significantly higher in the blood of men with more aggressive prostate tumours, and upon relapse to metastatic castrate resistant disease. This evidence concerns the gene ST6GAL1 and prostate carcinoma.